Literature DB >> 17962626

IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy.

Laura I Schrader1, Dale A Kinzenbaw, Andrew W Johnson, Frank M Faraci, Sean P Didion.   

Abstract

OBJECTIVE: The goal of this study was to test the hypothesis that IL-6 mediates the increases in superoxide, vascular hypertrophy, and endothelial dysfunction in response to angiotensin II (Ang II). METHODS AND
RESULTS: Responses of carotid arteries from control and IL-6-deficient mice were examined after acute (22-hour) incubation with Ang II (10 nmol/L) or chronic infusion of Ang II (1.4 mg/kg/d for 14 days). The hypertrophic response and endothelial dysfunction produced by Ang II infusion was markedly less in carotid arteries from IL-6-deficient mice than that in control mice. IL-6 deficiency also protected against endothelial dysfunction in response to acute (local) Ang II treatment (eg, 100 mumol/L acetylcholine produced 100+/-4 and 98+/-4% relaxation in vehicle-treated and 51+/-4 and 99+/-4% relaxation in Ang II-treated, control, and IL-6-deficient vessels, respectively). Endothelial dysfunction could be reproduced in vessels from IL-6-deficient mice with combined Ang II plus IL-6 (0.1 nmol/L) treatment. Increases in vascular superoxide and IL-6, as well as reductions in endothelial nitric oxide synthase mRNA expression, produced by Ang II were absent in IL-6-deficient mice.
CONCLUSIONS: These data demonstrate that IL-6 is essential for Ang II-induced increases in superoxide, endothelial dysfunction, and vascular hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962626     DOI: 10.1161/ATVBAHA.107.153080

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  81 in total

1.  Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.

Authors:  Michael W Brands; Amy K L Banes-Berceli; Edward W Inscho; Hind Al-Azawi; Ashlyn J Allen; Hicham Labazi
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it?

Authors:  Sean P Didion
Journal:  Hypertension       Date:  2011-04-25       Impact factor: 10.190

3.  Tetrahydrobiopterin deficiency and nitric oxide synthase uncoupling contribute to atherosclerosis induced by disturbed flow.

Authors:  Li Li; Wei Chen; Amir Rezvan; Hanjoong Jo; David G Harrison
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-21       Impact factor: 8.311

4.  Adipose tissue as regulator of vascular tone.

Authors:  Charlotte Boydens; Nele Maenhaut; Bart Pauwels; Kelly Decaluwé; Johan Van de Voorde
Journal:  Curr Hypertens Rep       Date:  2012-06       Impact factor: 5.369

Review 5.  Immune Mechanisms in Arterial Hypertension.

Authors:  Ulrich Wenzel; Jan Eric Turner; Christian Krebs; Christian Kurts; David G Harrison; Heimo Ehmke
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

6.  The frail renin-angiotensin system.

Authors:  Peter M Abadir
Journal:  Clin Geriatr Med       Date:  2011-02       Impact factor: 3.076

Review 7.  The immune system in hypertension.

Authors:  Daniel W Trott; David G Harrison
Journal:  Adv Physiol Educ       Date:  2014-03       Impact factor: 2.288

Review 8.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

9.  Interleukin-6 release after carotid artery stenting and periprocedural new ischemic lesions.

Authors:  Yuko Abe; Manabu Sakaguchi; Shigetaka Furukado; Toshiyuki Fujinaka; Saburo Sakoda; Toshiki Yoshimine; Kazuo Kitagawa
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-02       Impact factor: 6.200

10.  Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Authors:  Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.